RU2329263C2 - Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с - Google Patents
Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с Download PDFInfo
- Publication number
- RU2329263C2 RU2329263C2 RU2003115429/04A RU2003115429A RU2329263C2 RU 2329263 C2 RU2329263 C2 RU 2329263C2 RU 2003115429/04 A RU2003115429/04 A RU 2003115429/04A RU 2003115429 A RU2003115429 A RU 2003115429A RU 2329263 C2 RU2329263 C2 RU 2329263C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- denotes
- formula
- group
- compound
- Prior art date
Links
- 102000003923 Protein Kinase C Human genes 0.000 title claims abstract 4
- 108090000315 Protein Kinase C Proteins 0.000 title claims abstract 4
- OCQUNLGTYDFYDP-VURMDHGXSA-N (z)-2-(1h-indol-2-yl)but-2-enedioic acid Chemical compound C1=CC=C2NC(C(/C(O)=O)=C/C(=O)O)=CC2=C1 OCQUNLGTYDFYDP-VURMDHGXSA-N 0.000 title abstract 2
- 150000003949 imides Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 13
- 229910052799 carbon Inorganic materials 0.000 claims abstract 9
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 5
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 150000002367 halogens Chemical class 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 4
- 230000001154 acute effect Effects 0.000 claims abstract 3
- 230000001684 chronic effect Effects 0.000 claims abstract 3
- 210000000056 organ Anatomy 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- YINLOZXFQAVUKM-UHFFFAOYSA-N 3-[2-(4-ethylpiperazin-1-yl)quinazolin-4-yl]-4-(1h-indol-3-yl)pyrrole-2,5-dione Chemical compound C1CN(CC)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 YINLOZXFQAVUKM-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- OAVGBZOFDPFGPJ-UHFFFAOYSA-N sotrastaurin Chemical compound C1CN(C)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 OAVGBZOFDPFGPJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 15
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- -1 phenylC1-4alkyl Chemical group 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24640000P | 2000-11-07 | 2000-11-07 | |
| US60/246,400 | 2000-11-07 | ||
| US28370501P | 2001-04-13 | 2001-04-13 | |
| US60/283,705 | 2001-04-13 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008105345/04A Division RU2008105345A (ru) | 2000-11-07 | 2008-02-14 | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003115429A RU2003115429A (ru) | 2004-12-10 |
| RU2329263C2 true RU2329263C2 (ru) | 2008-07-20 |
Family
ID=26937956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003115429/04A RU2329263C2 (ru) | 2000-11-07 | 2001-11-05 | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с |
| RU2008105345/04A RU2008105345A (ru) | 2000-11-07 | 2008-02-14 | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008105345/04A RU2008105345A (ru) | 2000-11-07 | 2008-02-14 | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP1337527B1 (Direct) |
| JP (1) | JP4234426B2 (Direct) |
| KR (3) | KR100916613B1 (Direct) |
| CN (1) | CN1253449C (Direct) |
| AR (1) | AR035211A1 (Direct) |
| AT (1) | ATE445613T1 (Direct) |
| AU (3) | AU2181002A (Direct) |
| BR (1) | BRPI0115193B1 (Direct) |
| CA (1) | CA2428133C (Direct) |
| CY (1) | CY1110564T1 (Direct) |
| CZ (1) | CZ307144B6 (Direct) |
| DE (1) | DE60140201D1 (Direct) |
| DK (1) | DK1337527T3 (Direct) |
| EC (1) | ECSP104578A (Direct) |
| ES (1) | ES2332770T3 (Direct) |
| HU (1) | HU228999B1 (Direct) |
| IL (3) | IL155618A0 (Direct) |
| MX (1) | MXPA03004037A (Direct) |
| MY (2) | MY139979A (Direct) |
| NO (1) | NO327427B1 (Direct) |
| NZ (2) | NZ535616A (Direct) |
| PE (1) | PE20020544A1 (Direct) |
| PL (1) | PL208794B1 (Direct) |
| PT (1) | PT1337527E (Direct) |
| RU (2) | RU2329263C2 (Direct) |
| SG (1) | SG159378A1 (Direct) |
| SI (1) | SI1337527T1 (Direct) |
| SK (1) | SK287919B6 (Direct) |
| TW (2) | TWI290553B (Direct) |
| WO (1) | WO2002038561A1 (Direct) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10995052B2 (en) | 2016-02-03 | 2021-05-04 | Galderma Research & Development | Biaromatic propynyl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200918046A (en) | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
| WO2003103663A2 (en) * | 2002-06-05 | 2003-12-18 | Janssen Pharmaceutica N.V. | Substituted pyrrolines as kinase inhibitors |
| AU2003238874A1 (en) | 2002-06-05 | 2003-12-22 | Janssen Pharmaceutica N.V. | Bisindolyl-maleimid derivatives as kinase inhibitors |
| GB0303319D0 (en) * | 2003-02-13 | 2003-03-19 | Novartis Ag | Organic compounds |
| US8598146B2 (en) | 2003-09-16 | 2013-12-03 | Garvan Institute Of Medical Research | Methods for identifying modulators of protein kinase C-epsilon (PKCε) and method of treatment of aberrant glucose metabolism associated therewith |
| JP2007509185A (ja) * | 2003-10-27 | 2007-04-12 | ノバルティス アクチエンゲゼルシャフト | βアミロイド産生および／または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体 |
| CA2545340A1 (en) * | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
| GB0401089D0 (en) * | 2004-01-19 | 2004-02-18 | Novartis Ag | Organic compounds |
| PT1709030E (pt) * | 2004-01-19 | 2008-07-01 | Novartis Ag | Derivados da indolilmaleimida |
| EP1734952A1 (en) * | 2004-04-08 | 2006-12-27 | Novartis AG | Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection |
| GB0410713D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| WO2006061212A1 (en) | 2004-12-08 | 2006-06-15 | Johannes Gutenberg-Universität Mainz | 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors |
| GB0504203D0 (en) * | 2005-03-01 | 2005-04-06 | Novartis Ag | Organic compounds |
| GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
| EP1885454A2 (en) | 2005-05-04 | 2008-02-13 | DeveloGen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| GB0511060D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| KR20080023732A (ko) | 2005-07-11 | 2008-03-14 | 노파르티스 아게 | 인돌릴말레이미드 유도체 |
| CA2898369C (en) | 2005-10-26 | 2017-06-20 | Novartis Ag | Novel use of il-1beta compounds |
| PT2275103E (pt) | 2005-11-21 | 2014-07-24 | Novartis Ag | Inibidores de mtor para o tratamento de tumores endócrinos |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| GB0613162D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic compounds |
| CA2658835A1 (en) * | 2006-08-23 | 2008-02-28 | Novartis Ag | Use of pkc inhibitors in ocular diseases |
| MY158026A (en) * | 2006-10-20 | 2016-08-30 | Novartis Ag | Crystal modifications-3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2, 5-dione |
| KR20090087499A (ko) * | 2006-12-07 | 2009-08-17 | 노파르티스 아게 | 이식에서의 ｐｋｃ 억제제의 용도 |
| JP2010513386A (ja) * | 2006-12-19 | 2010-04-30 | ノバルティス アーゲー | キナーゼ阻害剤としてのインドリルマレイミド誘導体 |
| RU2487128C2 (ru) * | 2007-03-09 | 2013-07-10 | Новартис Аг | Соли 3-(1н-индол-3-ил)-4-[2-(4-метилпиперазин-1-ил)хиназолин-4-ил]пиррол-2,5-диона |
| KR20160017119A (ko) | 2007-05-29 | 2016-02-15 | 노파르티스 아게 | 항-ｉｌ-1-베타 치료법에 대한 신규 적응증 |
| KR20100075455A (ko) * | 2007-09-27 | 2010-07-02 | 노파르티스 아게 | 약물 모니터링 분석법 |
| WO2009060035A1 (en) | 2007-11-08 | 2009-05-14 | Novartis Ag | Gene expression signatures for chronic/sclerosing allograft nephropathy |
| AU2008333215B2 (en) | 2007-12-05 | 2013-06-13 | Johannes Gutenberg-Universitat Mainz | Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| CA2767616A1 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| RU2441000C2 (ru) * | 2009-11-27 | 2012-01-27 | Общество с ограниченной ответственностью "Молекулярные Технологии" | 4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения |
| EP2338486A1 (en) | 2009-12-18 | 2011-06-29 | Johannes Gutenberg-Universität Mainz | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma |
| EP2343291A1 (en) | 2009-12-18 | 2011-07-13 | Johannes Gutenberg-Universität Mainz | 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| US8791100B2 (en) | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
| WO2011120911A1 (en) | 2010-03-30 | 2011-10-06 | Novartis Ag | Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| EP2474541A1 (en) | 2010-12-23 | 2012-07-11 | Johannes- Gutenberg-Universität Mainz | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| CN102153605B (zh) * | 2011-03-02 | 2014-02-19 | 福建省微生物研究所 | 一种咪唑立宾的提纯方法 |
| UY34072A (es) * | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
| JP2014518256A (ja) | 2011-06-27 | 2014-07-28 | ノバルティス アーゲー | テトラヒドロ−ピリド−ピリミジン誘導体の固体形態および塩類 |
| GB201111427D0 (en) * | 2011-07-05 | 2011-08-17 | Amakem Nv | Novel bisindolylmaleimides, pan-pkc inhibitors |
| WO2013008095A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US20140249139A1 (en) | 2011-10-21 | 2014-09-04 | Novartis Ag | Quinazoline Derivatives |
| US20140348848A1 (en) | 2011-12-02 | 2014-11-27 | Dhananjay Kaul | Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease |
| PL2790705T3 (pl) | 2011-12-15 | 2018-06-29 | Novartis Ag | Zastosowanie inhibitorów czynności lub funkcji PI3K |
| WO2013093849A1 (en) | 2011-12-22 | 2013-06-27 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
| WO2013093850A1 (en) | 2011-12-22 | 2013-06-27 | Novartis Ag | Quinoline derivatives |
| EP2847191B1 (en) | 2012-05-09 | 2016-06-15 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
| IN2015DN02660A (Direct) | 2012-11-07 | 2015-09-04 | Novartis Ag | |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| WO2014085381A1 (en) | 2012-11-29 | 2014-06-05 | Novartis Ag | Pharmaceutical combinations |
| WO2014090398A1 (en) * | 2012-12-10 | 2014-06-19 | Centogene Ag | Use of maleimide derivatives for preventing and treating leukemia |
| EP2928465B1 (en) * | 2012-12-10 | 2020-11-18 | Centogene GmbH | Use of maleimide derivatives for preventing and treating cancer |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
| KR20160058889A (ko) | 2013-09-22 | 2016-05-25 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| EP3122729A4 (en) | 2014-03-28 | 2017-11-15 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
| EP3134396B1 (en) | 2014-04-24 | 2019-09-18 | Novartis AG | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
| JP6433509B2 (ja) | 2014-04-24 | 2018-12-05 | ノバルティス アーゲー | ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体 |
| BR112016023967A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de pirazina como inibidores de fosfatidilinositol 3-cinase |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| EP3146077A4 (en) | 2014-05-22 | 2018-05-02 | The Scripps Research Institute | Tissue molecular signatures of kidney transplant rejections |
| US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| AU2016308704B2 (en) | 2015-08-14 | 2019-06-20 | Novartis Ag | MDM2 inhibitors for treating uveal melanoma |
| US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| EP3187495A1 (en) | 2015-12-30 | 2017-07-05 | Johannes Gutenberg-Universität Mainz | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| WO2018175340A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
| WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
| JP7254076B2 (ja) | 2017-11-19 | 2023-04-07 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 置換ヘテロアリール化合物及び使用方法 |
| KR102737185B1 (ko) | 2018-01-20 | 2024-12-05 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 치환된 아미노피리미딘 화합물 및 이의 사용 방법 |
| CN110551103B (zh) * | 2018-05-30 | 2022-08-23 | 北京大学深圳研究生院 | 一种jak3选择性抑制剂 |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| CA3137790A1 (en) | 2019-05-23 | 2020-11-26 | Novartis Ag | Crystalline forms of a btk inhibitor |
| CA3182445A1 (en) | 2020-06-11 | 2021-12-16 | Francisco Leon | Methods and compositions for preventing type 1 diabetes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0328026A1 (de) * | 1988-02-10 | 1989-08-16 | F. Hoffmann-La Roche Ag | Substituierte Pyrrole |
| RU2126007C1 (ru) * | 1992-05-30 | 1999-02-10 | Гедеке АГ | Производные индолокарбазолимида, смесь их изомеров и их соли, фармацевтическая композиция с активностью, ингибирующей протеинкиназу c или киназу легкой миозиновой цепи или подавляющей иммунные реакции |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4066674A (en) | 1975-11-12 | 1978-01-03 | Schering Aktiengesellschaft | Process for the preparation of 1,3-oxygenated 8α-estratrienes and novel intermediates obtained therefrom |
| FR2637591B1 (fr) | 1988-10-11 | 1992-10-23 | Synthelabo | Derives de quinoleinone, leur preparation et leur application en therapeutique |
| HK1038564A1 (zh) * | 1998-10-08 | 2002-03-22 | Smithkline Beecham Plc | 用作糖原合酶激酶-3抑制劑的吡咯-2，5-二酮 |
| GB9828640D0 (en) * | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| HRP20030030A2 (en) * | 2000-07-27 | 2005-02-28 | F. Hoffmann - La Roche Ag | 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3- beta |
-
2001
- 2001-11-05 JP JP2002541095A patent/JP4234426B2/ja not_active Expired - Fee Related
- 2001-11-05 WO PCT/EP2001/012785 patent/WO2002038561A1/en not_active Ceased
- 2001-11-05 ES ES01993604T patent/ES2332770T3/es not_active Expired - Lifetime
- 2001-11-05 SG SG200502844-4A patent/SG159378A1/en unknown
- 2001-11-05 SK SK546-2003A patent/SK287919B6/sk not_active IP Right Cessation
- 2001-11-05 CA CA002428133A patent/CA2428133C/en not_active Expired - Fee Related
- 2001-11-05 RU RU2003115429/04A patent/RU2329263C2/ru not_active IP Right Cessation
- 2001-11-05 PL PL361409A patent/PL208794B1/pl unknown
- 2001-11-05 HU HU0301651A patent/HU228999B1/hu not_active IP Right Cessation
- 2001-11-05 AU AU2181002A patent/AU2181002A/xx active Pending
- 2001-11-05 KR KR1020067017472A patent/KR100916613B1/ko not_active Expired - Fee Related
- 2001-11-05 MX MXPA03004037A patent/MXPA03004037A/es active IP Right Grant
- 2001-11-05 SI SI200130954T patent/SI1337527T1/sl unknown
- 2001-11-05 AT AT01993604T patent/ATE445613T1/de active
- 2001-11-05 NZ NZ535616A patent/NZ535616A/xx not_active IP Right Cessation
- 2001-11-05 NZ NZ525656A patent/NZ525656A/xx not_active IP Right Cessation
- 2001-11-05 DK DK01993604T patent/DK1337527T3/da active
- 2001-11-05 DE DE60140201T patent/DE60140201D1/de not_active Expired - Lifetime
- 2001-11-05 PT PT01993604T patent/PT1337527E/pt unknown
- 2001-11-05 CZ CZ2003-1266A patent/CZ307144B6/cs not_active IP Right Cessation
- 2001-11-05 AR ARP010105176A patent/AR035211A1/es not_active Application Discontinuation
- 2001-11-05 EP EP01993604A patent/EP1337527B1/en not_active Expired - Lifetime
- 2001-11-05 KR KR1020087002849A patent/KR20080014934A/ko not_active Ceased
- 2001-11-05 PE PE2001001093A patent/PE20020544A1/es not_active Application Discontinuation
- 2001-11-05 EP EP09151894A patent/EP2070921A1/en not_active Withdrawn
- 2001-11-05 AU AU2002221810A patent/AU2002221810B2/en not_active Ceased
- 2001-11-05 BR BRPI0115193A patent/BRPI0115193B1/pt not_active IP Right Cessation
- 2001-11-05 CN CNB018199925A patent/CN1253449C/zh not_active Expired - Fee Related
- 2001-11-05 KR KR1020037005805A patent/KR100748386B1/ko not_active Expired - Fee Related
- 2001-11-05 IL IL15561801A patent/IL155618A0/xx active IP Right Grant
- 2001-11-06 MY MYPI20055681A patent/MY139979A/en unknown
- 2001-11-06 MY MYPI20015097A patent/MY127157A/en unknown
- 2001-11-07 TW TW090127656A patent/TWI290553B/zh not_active IP Right Cessation
- 2001-11-07 TW TW096118830A patent/TW200738687A/zh unknown
-
2003
- 2003-04-28 IL IL155618A patent/IL155618A/en not_active IP Right Cessation
- 2003-05-06 NO NO20032034A patent/NO327427B1/no not_active IP Right Cessation
-
2005
- 2005-06-01 AU AU2005202387A patent/AU2005202387B2/en not_active Ceased
-
2007
- 2007-04-10 IL IL182428A patent/IL182428A0/en unknown
-
2008
- 2008-02-14 RU RU2008105345/04A patent/RU2008105345A/ru not_active Application Discontinuation
-
2009
- 2009-11-25 CY CY20091101228T patent/CY1110564T1/el unknown
-
2010
- 2010-03-11 EC EC2010004578A patent/ECSP104578A/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0328026A1 (de) * | 1988-02-10 | 1989-08-16 | F. Hoffmann-La Roche Ag | Substituierte Pyrrole |
| RU2126007C1 (ru) * | 1992-05-30 | 1999-02-10 | Гедеке АГ | Производные индолокарбазолимида, смесь их изомеров и их соли, фармацевтическая композиция с активностью, ингибирующей протеинкиназу c или киназу легкой миозиновой цепи или подавляющей иммунные реакции |
Non-Patent Citations (2)
| Title |
|---|
| J. of Medicinal Chemistry, v.35, n.1, 1992, p.177-184. * |
| приоритет от 07.11.2000 по п.1, где R означает группу формулы d) и формулы е) и Е означает -N=, a G означает -СН=, а также соединения по примерам 165, 168, 169. приоритет от 13.04.2001 по п.1, где R означает группу формулы е) и Е означает -СН=, a G означает -N=. Приоритет от 07.11.2000 и от 13.04.2001 для пп.2-10 в равной степени. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10995052B2 (en) | 2016-02-03 | 2021-05-04 | Galderma Research & Development | Biaromatic propynyl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof |
| RU2753863C2 (ru) * | 2016-02-03 | 2021-08-24 | Галдерма Ресерч Энд Девелопмент | Новые биароматические соединения пропинила, фармацевтические и косметические композиции, их содержащие, и их применение |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2329263C2 (ru) | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с | |
| RU2003115429A (ru) | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с | |
| RU2394826C2 (ru) | Дизамещенные пиразолобензодиазепины, используемые в качестве ингибиторов cdk2 и ангиогенеза, а также для лечения злокачественных новообразований молочной железы, толстого кишечника, легкого и предстательной железы | |
| RU2430923C2 (ru) | Тиазолилдигидрохиназолины | |
| RU2336275C2 (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция | |
| RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| RU2356891C2 (ru) | Производные пиридинкарбоксамида и их соли для применения в качестве инсектицида | |
| RU2401260C2 (ru) | Пиримидиновые производные | |
| RU2004132203A (ru) | Индолилмалеимидные производные | |
| RU2007139453A (ru) | Гетеробициклические ингибиторы вируса гепатита с (hcv) | |
| ATE472537T1 (de) | 2,4-di(hetero-)arylamino(-oxy)-5-substituierte pyrimidinderivate als antineoplastika | |
| RU2009101298A (ru) | Гетероциклические соединения в качестве усилителей подслащивающего вещества | |
| RU2004106783A (ru) | Производные 4-амино-6-фенилпирроло[2, 3] пиримидина | |
| JP2004513168A5 (Direct) | ||
| ATE448226T1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| RU2395507C2 (ru) | Пиримидиновые производные | |
| EA200100766A1 (ru) | Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов | |
| JP2004522755A5 (Direct) | ||
| WO2001038324A3 (en) | Imidazole derivatives and their use as raf kinase inhibitors | |
| RU2009115963A (ru) | Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами | |
| RU2006112593A (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk | |
| EA200100486A1 (ru) | Производные 2-уреидотиазола, способ их получения и применение указанных веществ в качестве противоопухолевых средств | |
| JP2005508336A5 (Direct) | ||
| RU2007100134A (ru) | Пиразолпиримидины | |
| RU2006128788A (ru) | Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171106 |